INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10752411
Filing Date		2004-01-07
First Named Inventor Karen		Jackson
Art Unit		1611
Examiner Name	Josep	oh S. Kudia
Attorney Docket Number		330499-00025

Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
1	5550126		1996-08-27	Horwell, et al.	
2	5760032		1998-06-02	-02 Kitajima, et al.	
3	5798353		1998-08-25	Badoro, et al.	
4	6344452		2002-02-05	Shinozaki, et al.	
5	5153191		1992-10-06	Woodruff	
h to ac	d additional U.S. Paten	t citatio	n information pl	ease click the Add button.	Add
		U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove
Cite No	Publication Number			Name of Patentee or Applicant of cited Document Pages, Columns, Lines who Relevant Passages or Rele Figures Appear	
1	20040043990		2004-03-04	Jackson	
	1 2 3 4 5 Cite No	No Patient Number  1 5550126  2 5760032  3 5796353  4 6344452  5 5153191  To add additional U.S. Paten No	No   Patent Number   Code1	No   Patent Number   Code   Susue Date	No

U.S. PATENTS

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10752411
Filing Date		2004-01-07
First Named Inventor	Karen	Jackson
Art Unit		1611
Examiner Name Josep		h S. Kudla
		200400 00000

				_				
	2	20030139396	2003-07	-24	Gibson			
If you wis	h to a	dd additional U.S. Publi	shed Application	citatio	n information p	please click the Add but	ton. Add	
			FOREIG	SN PAT	TENT DOCUM	ENTS	Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> į	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TS
	1	9918967	wo		1999-04-22	THERAPEUTICS LIMITED		
	2	03061632	wo		2003-07-31	KAREN JACKSON		
	3	0517412	EP		1992-12-09	MERCK SHARP & DOHME		
	4	0434364	EP		1991-06-26	MERK & CO., INC.		
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								_
NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Initials*							Ţ5	
	1	L BUENO, "Involvement of Brain COX in the Adaptation of Gut Motitity to Digestive Status and Stress": A review, J [Physiology (1983) vol. 87, pp. 301-306						
	2	J. FIGRAMONTI, et al., "Involvement of a CCK-Dependent Capsaion-Sensitive Afferent Pathway in the Inhibitory Effect of Pinaverium Bromide on the Colonic Motor Response to Eating in Rats", Fundam Clin Pharmacol 1997.11 231-236						

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10752411		
Filing Date		2004-01-07		
First Named Inventor	Karen Jackson			
Art Unit		1611		
Examiner Name	Joseph S. Kudla			
Attorney Docket Number		330499-00025		

EXAMINER SIGNATURE						
If you wish to add additional non-patent literature document citation information please click the Add button Add						
	11	CHANG, et al., 'Proc. Natl. acad. Sci. USA, Vol. 83, pp. 4923-26, 1986				
	10	SHIPTON, "South African J. Anesthesiology & Analgesia, Vol 6, #2, pp. 1-12, 2000				
	9	JOEL HARDMAN, et al., "Goodman & Gilman's The Pharmacological basis of Therapeutics, 9th Edition, 1996, pp. 526-529 and 540-545				
	8	C.T. DOURISH, et al., "The Cholecystokinin Receptor Antagonist Devazeptic Enhances Morphine-Induced Respiratory Degression in the Squirrel Morkey", The Journal of Pharmacology and Experimental Theraputics, vol. 255, No. 3, 1990, pp. 1159-1164				
	7	L. SINGH, et al., "Modulation of the in Vivo actions of Morphine by the Mixed CCKA/B Receptor Antagonet PD 142988", European Journal of Pharmacology, Amsterdam, NL, 307(3) 1995, pp. 283-2891				
	6	CYNTHIA WILLIAMS, et al., "Cholerystokinn-induced Antimodoeption is Not Blooked by CCCK-A or CCCK-B Receptor Antiagonists", Peptides (Terryfown), 18(3) 1997 pp. 409-414				
	5	J.G. WETTSTEIN, et al., "CCK Antagonists: Pharmacology And Thereputic Interest", Pharmac. Ther., (1994), vol 62, pp. 267-282				
	4	M. D'AMATO, et al., "Cholecystokinin-A Receptor Antagonists: Therapies for Gastrointestinal Disorders", Exp. Opin. Invest. Drugs (1997) 6(7) pp. 819-836				
	3	C BEGLINGER, "Effect of Cholecystokinin on Gastric Motility in Humans", 1994, Annais New York Academy of Sciences, Vol. 713, Issue 1, pp. 219-225				

Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 GFR 1.99)	Application Number		10752411	
	Filing Date		2004-01-07	
	First Named Inventor Karer		Jackson	
	Art Unit		1611	
	Examiner Name	Josep	oh S. Kudla	
	Attorney Docket Numb	er	330499-00025	

See Kind Code of USPTO Petert Documents at invest, ISETIG.ODV or MEPF 961.04. It better dots that issued the document, by the lockletic code (WIPO Standard S13.) If the planeses patient focusment, the includation of the parent for the grant or the representation process the sensal number of the patient for expented or the parent for the patient focus of the parent for the patient focus or the parent foc